Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of O6-Benzylguanine Combined With Carmustine in Patients With Previously Untreated or Refractory Multiple Myeloma

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	Not specified	NCI	CWRU-1A96 NCI-T97-0021, NCT00004072, T97-0021

Trial Description

Purpose:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Phase II trial to study the effectiveness of combining O6-benzylguanine with carmustine in treating patients who have previously untreated, refractory, or relapsing multiple myeloma.

Eligibility:

• At least 4 weeks since chemotherapy
• No previous radiation therapy to the pelvis
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive infusions of O6-benzylguanine and carmustine every 6 weeks for as long as benefit is shown. Patients will receive follow-up evaluations every 2 months.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Ireland Cancer Center at University Hospitals/Case Medical Center

Stanton Gerson, MD, Protocol chair		Ph: 216-844-8562

Registry Information
Official Title		Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU in Patients with Multiple Myeloma
Trial Start Date		1999-09-21
Registered in ClinicalTrials.gov		NCT00004072
Date Submitted to PDQ		1999-08-25
Information Last Verified		2004-07-26
NCI Grant/Contract Number		P30-CA43703, U01-CA62502

Back to Top